Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.5%

Rapport Therapeutics (NASDAQ:RAPP)’s stock price fell 6.5% on Wednesday . The company traded as low as $23.93 and last traded at $24.18. 90,930 shares changed hands during trading, a decline of 63% from the average session volume of 242,660 shares. The stock had previously closed at $25.87.

Wall Street Analyst Weigh In

A number of research firms have weighed in on RAPP. Jefferies Financial Group began coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price target for the company. Stifel Nicolaus began coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price target for the company. Finally, TD Cowen began coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating for the company.

Rapport Therapeutics Trading Down 4.9 %

Insider Transactions at Rapport Therapeutics

In related news, Director James Healy acquired 44,032 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were bought at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the purchase, the director now directly owns 40,851 shares in the company, valued at approximately $1,001,666.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.